# SNDX catalysts: Syndax Pharmaceuticals Inc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sndx/catalysts

> Syndax Pharmaceuticals Inc (SNDX) has 9 upcoming catalysts. The next is the SNDX-4321 trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SNDX?

Syndax Pharmaceuticals Inc (SNDX) has 9 upcoming catalysts. The next is the SNDX-4321 trial start, 2027. Press release filed with the SEC (EX-99): "The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027." [Calendar and source filings](https://sec-api.dev/companies/sndx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-443613, https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-02. Cite: https://sec-api.dev/companies/sndx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Syndax Pharmaceuticals Inc |
| Ticker | SNDX (Nasdaq) |
| SEC CIK | 1395937 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sndx |

## Cash runway

Cash $551.1M as of 2026-09-30; quarterly burn $27.3M; about 60.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-443625).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2024 | [NIKTIMVO (axatilimab) FDA approval](https://sec-api.dev/pdufa/axatilimab) | SNDX | chronic graft-versus-host disease, or cGVHD | completed, approved | "Niktimvo (axatilimab-csfr) is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm)) |
| Aug 2024 | [Revuforj® (revumenib) FDA approval](https://sec-api.dev/pdufa/revumenib) | SNDX | chronic graft-versus-host disease, or cGVHD | completed, approved | "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443625/sndx-20260930.htm)) |
| November 12, 2024 | [Revuforj® (revumenib) topline data readout](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, positive | "WALTHAM, Mass., November 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm)) |
| November 15, 2024 | [Revuforj® (revumenib) FDA approval](https://sec-api.dev/pdufa/revumenib) | SNDX | To treat relapsed or refractory acute leukemia | completed, approved | "Revuforj \| revumenib \| 11/15/2024 \| To treat relapsed or refractory acute leukemiaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| December 26, 2024 | [Revuforj® (revumenib) PDUFA date](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "Positive data from the KMT2Ar AML and ALL patients in the trial supported a New Drug Application (NDA) filing for revumenib in R/R KMT2Ar acute leukemia, which is currently under review by the U.S. FDA with a PDUFA action date of December 26, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm)) |
| March 3, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-ex99_1.htm)) |
| Q2 2025 | [Revuforj® (revumenib) NDA/BLA submission](https://sec-api.dev/pdufa/revumenib) | SNDX |  | scheduled | "The Company expects to submit a supplemental NDA (sNDA) filing for revumenib in R/R mNPM1 AML in the second quarter of 2025, followed by a potential FDA approval around year-end 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-ex99_1.htm)) |
| Apr 2025 | [Revuforj® (revumenib) NDA/BLA submission](https://sec-api.dev/pdufa/revumenib) | SNDX | R/R mutant NPM1 | completed | "Completed the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA in April 2025, seeking Priority Review for the approval of Revuforj for the treatment of R/R mutant NPM1 (mNPM1) AML." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-ex99_1.htm)) |
| May 5, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-ex99_1.htm)) |
| June 30, 2025 | [Revuforj® (revumenib) NDA/BLA submission](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed | "In the three months ended June 30, 2025 the Company the submitted an supplemental New Drug Application (sNDA) to the U.S. FDA for a second indication for Revuforj." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm)) |
| August 4, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm)) |
| October 24, 2025 | [Revuforj® (revumenib) FDA approval](https://sec-api.dev/pdufa/revumenib) | SNDX | relapsed or refractory | completed, approved | "On October 24, 2025, Syndax Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) for the treatment of relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a susceptible nucleophosmin 1 ("NPM1") mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-20251024.htm)) |
| October 24, 2025 | [Revuforj® (revumenib) label expansion decision](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "NDA218944 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20251024, review_priority PRIORITY; sponsor_name SYNDAX; product REVUFORJ (REVUMENIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218944%22)) |
| October 25, 2025 | [Revuforj® (revumenib) PDUFA date](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed, approved | "PDUFA target action date of October 25, 2025 IC, intensive chemotherapy" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_2.htm)) |
| October 25, 2025 | [NIKTIMVO (axatilimab) PDUFA date](https://sec-api.dev/pdufa/axatilimab) | SNDX |  | scheduled | "- sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm)) |
| Nov 2025 | [Revuforj® (revumenib) trial start](https://sec-api.dev/pdufa/revumenib) | SNDX |  | completed | "Initiated REVEAL-ND, a Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed patients with NPM1m AML in November 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-ex99_1.htm)) |
| November 3, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/sndx-ex99_1.htm)) |
| 2026 | [Revuforj® (revumenib) trial start](https://sec-api.dev/pdufa/revumenib) | SNDX |  | scheduled | "Initiate RAVEN, a Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible, or fit, for intensive chemotherapy in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-ex99_1.htm)) |
| January 12, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "NEW YORK, January 12, 2026 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced preliminary, unaudited fourth quarter and full year 2025 financial results and provided additional business updates ahead of its presentation at the 44th Annual J.P. Morgan Healthcare conference." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-ex99_1.htm)) |
| February 26, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-ex99_1.htm)) |
| April 30, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-ex99_1.htm)) |
| 2H 2026 | [Revuforj® (revumenib) topline data readout](https://sec-api.dev/pdufa/revumenib) | SNDX |  | scheduled | "Trial initiation anticipated in 4Q25 Dual primary endpoints: MRD negative CR & EFS to support potential for accelerated and full approval, respectively Topline MAXPIRe data anticipated in 2H26 Enrollment underway in EVOLVE-2 Dual primary endpoints: CR and OS in mNPM1 pts. to support potential for accelerated and full approval, respectively" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_2.htm)) |
| August 4, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-ex99_1.htm)) |
| August 27, 2026 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | SNDX | Idiopathic Pulmonary Fibrosis | completed | "NCT06132256 (MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Syndax Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132256)) |
| Q4 2026 | [Syndax Pharmaceuticals Inc topline data readout](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | scheduled | "Topline data are anticipated in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-ex99_1.htm)) |
| November 2, 2026 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm)) |
| 2027 | [SNDX-4321 trial start](https://sec-api.dev/pdufa/sndx-4321) | SNDX |  | scheduled | "The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm)) |
| Q1 2027 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | SNDX |  | scheduled | "The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm)) |
| early 2027 | [Syndax Pharmaceuticals Inc topline data readout](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | scheduled | "Topline data from the trial is anticipated in early 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm)) |
| early 2027 | [Syndax Pharmaceuticals Inc topline data readout](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | scheduled | "Global enrollment underway in pivotal 1L trials with dual primary endpoints to support potential for accelerated and full approval 1L, maintenance, & real-world data anticipated throughout 2026 at major medical meetings Two ongoing 1L cGVHD trials; topline axa + rux data anticipated early 2027 and axa + steroids early 2028 Completed enrollment in MAXPIRe; topline data anticipated in 4Q26" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-ex99_2.htm)) |
| 2H 2027 | [Revuforj® (revumenib) interim data readout](https://sec-api.dev/pdufa/revumenib) | SNDX |  | scheduled | "The development of SNDX-62122 will be informed by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm)) |
| Q4 2027 | [SNDX-62122 trial start](https://sec-api.dev/pdufa/sndx-62122) | SNDX |  | scheduled | "The Company expects to submit an IND and initiate a Phase 1 trial of SNDX-62122 in MF in the fourth quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm)) |
| early 2028 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | SNDX |  | scheduled | "The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm)) |
| June 2029 | [Revuforj® (revumenib) primary completion](https://sec-api.dev/pdufa/revumenib) | SNDX | Acute Myeloid Leukemias | scheduled | "NCT07211958 (Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Syndax Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211958)) |
| Jun to Sep 2029 | [Revuforj® (revumenib) topline data readout](https://sec-api.dev/pdufa/revumenib) | SNDX | Acute Myeloid Leukemias | scheduled | "NCT07211958 (Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Syndax Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07211958)) |

## Drugs

- [Revuforj® (revumenib)](https://sec-api.dev/pdufa/revumenib): relapsed or refractory, or r/r, acute leukemia, chronic graft-versus-host disease, or cgvhd, relapsed or refractory, r/r acute leukemia, r/r acute myeloid leukemia, r/r mutant npm1, To treat relapsed or refractory acute leukemia, Acute Myeloid Leukemias
- [SNDX-4321](https://sec-api.dev/pdufa/sndx-4321): 
- [SNDX-62122](https://sec-api.dev/pdufa/sndx-62122): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sndx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SNDX catalysts: Syndax Pharmaceuticals Inc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sndx/catalysts

```bibtex
@misc{secapidev_companies_sndx_catalysts_20261116,
  title        = {SNDX catalysts: Syndax Pharmaceuticals Inc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sndx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sndx_catalysts_20261116","title":"SNDX catalysts: Syndax Pharmaceuticals Inc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sndx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
